Lifeflower® Breviscapine (Erigeron Breviscapus Extract)

• Helps to support healthy Brain and Blood Circulation*
• Helps with mild memory loss associated with Aging*
• Helps with Clarity & Focus associated with Cognitive Health*

LifeFlower® Breviscapine (Erigeron Breviscapus extract) is a patented and branded ingredient that contains at least 90% of scutellarin as the primary bioactive compound. It is extracted from Erigeron Breviscapus, a medicinal plant that has been used for over 500 years. LifeFlower® Breviscapine is GRAS self-affirmed to be used as an ingredient in food, beverage and dietary supplement. The recommended dosage is 200mg per person per day as dietary supplement, 84mg per person per serving in food and beverage.

• BRE-002 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥98%, HPLC)
• BRE-003 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥90%, HPLC)
• Molecular Formula: C12H18O12
• Molecular Weight: 462.36
• CAS#: 116122-36-2
• Chemical Nature: Dietary Ingredient
• Common Name: Erigeron Breviscapus Extract, Scutellarin, Breviscapinum

• NOT-003 Ginseng Plus® Panax Notoginseng Extract (Total Saponins ≥85%, HPLC)
• NOT-004 Ginseng Plus® Panax Notoginseng Extract (Total Saponins ≥75%, HPLC)
• NOT-005 Panax Notoginseng Raw Powder (100 Mesh) (Total Saponins ≥5%, HPLC)
• NOT-006 Panax Notoginseng Root Ultrafine Raw Powder (200 Mesh) (Total Saponins ≥5%, HPLC)
• FLI-10 Panax Notoginseng Root Steamed Powder (Total Saponins ≥4.5%, HPLC)

• GAP Cultivation
• cGMP Manufacturing
• GSP Logistic & Warehousing
• Independent Verify Quality
• FDA Compliance

Additional studies of breviscapine or scutellarin are documented on the PubMed.gov website, NCBI (US National Library of Medicine National Institute of Health). Search using key words: Breviscapine, Scutellarin, Erigeron Breviscapus

SCIENTIFIC NAME: Erigeron breviscapus	FAMILY NAME: Asteraceae
COMMON NAME: lifeflower, duan ting fei peng
Evidence for Efficacy (Human Data)	Safety Data
Clinical Trials (4)	Adverse Effects & Toxicity (0)
Observational Studies/Case Reports (1)	Interactions (5)
Traditional and Folk Use (0)	Contraindications (0)
Evidence of Activity	Formulas/Blends
Animal Studies (53)	Modern Methods of Preparation (7)
Pharmacodynamics (33)	Patents (0)
Analytical Chemistry (26)
Pharmacokinetics (ADME) (13)
Genetics (11)
Literature Reviews (6)
Other Information	Dynamic Updates
Pictures & Distribution Maps (1)	Live PubMed Searches (15)
Cultivation, Conservation & Ecology (9)
Related Links (2)
History of record

ORIGINAL RESEARCH BY: Selena Rowan July 2019
LATEST UPDATES BY: Selena Rowan February 2020

Link to American Botanical Council & All Research

• Baked Food
• Sports Drink
• Smoothie
• Yoghurt
• Dietary Supplement

200mg/day as Supplement
84mg/day as Food & Beverage Ingredient

• Light Yellow Fine Powder
• Neutral Taste

ing Ma 2017a. A Single Dose Toxicity Study of Breviscapine for Injection in Sprague Dawley Rats via Intravenous Injection. Study No. 1610AD1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. May 23, 2018, pp. 64.

Jing Ma 2017b. The toxicity test data and literature for rats with repeated administration. The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period. Study No. 1016RD1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 28, 2018, summary of test results, pp. 4.

Jing Ma 2017c. The toxicity test data and literature for Beagle dogs with repeated administration. The toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in the 4-week recovery period. Study No. 1016RD2. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 28, 2018, summary of test results, pp. 3.

Jing Ma 2017d. Test data and literature for anaphylactic (systemic) special safety. Active systemic anaphylaxis test for guinea pigs with the administration of breviscapine injection. Study No. 1610HY2. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 4, 2018, summary of test results, pp. 3.

Jing Ma 2017e. Test data and literature for the special safety of hemolysis. Hemolysis test for the breviscapine injection. Study No. 1610HL1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. May 14, 2018, summary of test results, pp. 2.

Jing Ma 2017f. The toxicity test data and literature for rats with repeated administration. The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapineinjection in 4-week recovery period with micronucleus test. Study No. 1016RD1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 28, 2018, summary of test results, pp. 4.

Jing Ma 2017g. Test data and literature of genetic toxicity. Bacterial reverse mutation test for the breviscapine injection. Study No. 1610AM1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. April 19, 2018, summary of test results, pp. 2.

Jing Ma 2017h. Genetic toxicity test data and literature. The micronucleus test on SD rats receiving intravenous injection with breviscapine injection. The accompanied toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period. Study No. 1610RD1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 28, 2018, summary of test results, pp. 2.

Jing Ma 2017i. Test data and literature of genetic toxicity. The chromosome aberration test on Chinese hamster lung fibroblast cell line for the breviscapine injection. Study No. 1016CA1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. April 9, 2018, summary of test results, pp. 3.

Jing Ma 2017j. Test data and literature for genetic toxicity. The comet assay on SD rats receiving the intravenous injection with breviscapine injection. Study No. 1610CO1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. July 6, 2018, summary of test results, pp. 3.

Jing Ma 2017k. Test data and literature for reproductive toxicity. The toxicity test of reproduction and early embryonic development for SD rats receiving the intravenous injection with breviscapine injection. Study No. 1610RA1. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. March 14, 2018, summary of test results, pp. 3.

Jing Ma 2017l. Test data and literature for special safety of local irritation. The irritation test on administration sites of Beagle dogs receiving intravenous injection with breviscapine injection. The accompanied toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period. Study No. 1016RD2. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. March 14, 2018, summary of test results, pp. 2.

Jing Ma 2017m. Test data and literature for anaphylactic (systemic) special safety. The passive cutaneous anaphylaxis test for rats receiving the breviscapine injection. Study No. 1016HY4. Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar). National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER). 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China. June 4, 2018, summary of test results, pp. 3.

*Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, treat, or prevent any disease.

Shop our Lifeflower product here.

To order our raw materials, call us at 1-888-327-5664, e-mail us at [email protected] or fill out the form below.